Recurrent Stroke Prevention Clinical Outcome Study

PHASE4UnknownINTERVENTIONAL
Enrollment

5,000

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2019

Conditions
HypertensionStrokeBlood Pressure
Interventions
DRUG

Losartan, Losartan and HCTZ, Amlodipine , Spironolactone

\<Study drugs and treatment steps\> Step 1: Losartan 50 mg in principle (other ARB is usable) Step 2: Combination drug containing losartan 50 mg and hydrochlorothiazide 12.5 mg Step 3: Combination drug containing losartan 50mg and HCTZ 12.5mg + amlodipine 5 mg Step 4: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 5 mg Step 5: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg Step 6: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg + spironolactone 25 mg

Trial Locations (1)

329-0498

RECRUITING

Jichi Medical Univercity, Shimotsuke

Sponsors
All Listed Sponsors
lead

Biomedis International Ltd.

OTHER